Hippo信号通路在乳腺癌中的调控机制及作用

doi:10.16288/j.yczz.17-100

[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2017, Vol. 39 ›› Issue (7): 617-629.doi: 10.16288/j.yczz.17-100

Previous Articles Next Articles

The regulatory mechanisms and functional roles of the Hippo signaling pathway in breast cancer

Chuanbo Yao¹(),Xin Zhou²(),Ceshi Chen³,Qunying Lei¹(),

1. Cancer Institute, Fudan University Shanghai Cancer Center and Cancer Metabolism Laboratory of Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China
2. Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston 77030, USA
3. Laboratory of Cancer Biology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China

Received:2017-03-23 Revised:2017-04-14 Online:2017-07-20 Published:2017-06-08
Supported by:
the National Basic Research Program of China (973 Program)(2015CB910401);the National Natural Science Foundation of China(81430057,81572686)

Abstract

Abstract:

Hippo signaling pathway has attracted broad attention due to its essential roles in controlling organ size and tumorigenesis. TAZ/YAP, two core downstream molecules of the Hippo signaling pathway in mammals, are tightly regulated by a wide range of extracellular and intrinsic signals in both Hippo signaling pathway-dependent and -independent manners. Besides their roles in the development and function of normal mammary glands, TAZ/YAP display remarkable potency and relevance to multiple aspects of human breast carcinogenesis, including cellular proliferation, differentiation, apoptosis, migration, invasion, epithelial-mesenchymal transition and stemness. In this review, we summarize the regulators of TAZ/YAP, discuss the significant contribution of the Hippo signaling pathway to human breast cancers and highlight their potential therapeutic roles.

Key words: TAZ/YAP, Hippo signaling pathway, breast cancer

Chuanbo Yao, Xin Zhou, Ceshi Chen, Qunying Lei, . The regulatory mechanisms and functional roles of the Hippo signaling pathway in breast cancer[J]. Hereditas(Beijing), 2017, 39(7): 617-629.

References

[1]	Siegel R, Ma JM, Zou ZH, Jemal A. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29.
[2]	Perou CM, S?rlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge ?, Pergamenschikov A, Williams C, Zhu SX, L?nning PE, B?rresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.
[3]	The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490(7418): 61-70.
[4]	Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov, 2014, 13(1): 63-79.
[5]	Zhao B, Wei XM, Li WQ, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu JD, Li L, Zheng P, Ye KQ, Chinnaiyan A, Halder G, Lai ZC, Guan KL. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev, 2007, 21(21): 2747-2761.
[6]	Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao SM, Xiong Y, Guan KL. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol, 2008, 28(7): 2426-2436.
[7]	Cui CB, Cooper LF, Yang XL, Karsenty G, Aukhil I. Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol, 2003, 23(3): 1004-1013.
[8]	Jeong H, Bae S, An SY, Byun MR, Hwang JH, Yaffe MB, Hong JH, Hwang ES. TAZ as a novel enhancer of MyoD-mediated myogenic differentiation. FASEB J, 2010, 24(9): 3310-3320.
[9]	Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science, 2005, 309(5737): 1074-1078.
[10]	Park KS, Whitsett JA, Di Palma T, Hong JH, Yaffe MB, Zannini M. TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. J Biol Chem, 2004, 279(17): 17384-17390.
[11]	Murakami M, Tominaga J, Makita R, Uchijima Y, Kurihara Y, Nakagawa O, Asano T, Kurihara H. Transcriptional activity of Pax3 is co-activated by TAZ. Biochem Biophys Res Commun, 2006, 339(2): 533-539.
[12]	Di Palma T, D'Andrea B, Liguori GL, Liguoro A, de Cristofaro T, Del Prete D, Pappalardo A, Mascia A, Zannini M. TAZ is a coactivator for Pax8 and TTF-1, two transcription factors involved in thyroid differentiation. Exp Cell Res, 2009, 315(2): 162-175.
[13]	Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW, Wrana JL. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol, 2008, 10(7): 837-848.

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

The regulatory mechanisms and functional roles of the Hippo signaling pathway in breast cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments